EMA Authorised: Anzupgo (Delgocitinib) — LEO Pharma A/S

View source ↗

Summary

The European Medicines Agency authorised Anzupgo (delgocitinib) by LEO Pharma A/S for dermatitis and eczema in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis
• Dermatitis

Drugs mentioned

• ANZUPGO (delgocitinib)

Snippet

Status: Authorised. Therapeutic area: Dermatitis;Eczema. MAH: LEO Pharma A/S. Decision date: 23/10/2025